
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYMBRAVO | Axsome Therapeutics | N-215431 RX | 2025-01-30 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| maxalt | New Drug Application | 2011-09-13 |
| maxalt maxalt-mlt | New Drug Application | 2025-09-01 |
| maxalt-mlt | New Drug Application | 2011-04-04 |
| rizafilm | New Drug Application | 2024-01-10 |
| rizatriptan | ANDA | 2024-08-29 |
| rizatriptan benzoate | ANDA | 2025-08-20 |
| rizatriptan benzoate odt | ANDA | 2025-01-22 |
| rizatriptan benzoate rizatriptan benzoate | ANDA | 2021-03-02 |
| symbravo | New Drug Application | 2025-02-24 |
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Rizatriptan Benzoate, Rizafilm, Gensco | |||
| 9301948 | 2034-07-30 | DS, DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
| Drug common name | Rizatriptan |
| INN | rizatriptan |
| Description | Rizatriptan is a member of tryptamines. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is functionally related to a N,N-dimethyltryptamine. |
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12 |
| PDB | — |
| CAS-ID | 144034-80-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL905 |
| ChEBI ID | 48273 |
| PubChem CID | 5078 |
| DrugBank | DB00953 |
| UNII ID | 51086HBW8G (ChemIDplus, GSRS) |






